Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30510222 | 1.00 | CYP1A2 (0.30) | CYP1A2TSHR | |
| SCHEMBL25173117 | 0.89 | CETP (0.31) | CYP1A2TSHR | |
| SCHEMBL25182298 | 0.88 | PPIA (0.33) | CYP1A2TSHR | |
| SCHEMBL30510415 | 0.88 | ALDH1A1 (0.33) | CYP1A2TSHR | |
| SCHEMBL25179602 | 0.88 | ALDH1A1 (0.33) | CYP1A2TSHR | |
| SCHEMBL25185739 | 0.82 | CTSB (0.37) | — | |
| SCHEMBL30510321 | 0.81 | PPARG (0.39) | — | |
| SCHEMBL25178742 | 0.81 | PPARG (0.39) | — | |
| SCHEMBL25173049 | 0.81 | ALDH1A1 (0.34) | CYP1A2 | |
| SCHEMBL30510414 | 0.81 | PPARG (0.33) | CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | CYP1A2 4845/4885TSHR 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.